LakeShore Biopharma Receives Revised Acquisition Offer Amid Financial Review LakeShore Biopharma has received a revised proposal to acquire outstanding shares at a reduced price, as the company navigates financial challenges.

LakeShore Biopharma Receives Revised Acquisition Offer Amid Financial Review #China #Beijing #LakeShore_Biopharma #Merger_Proposal #Oceanpine_Skyline

LakeShore Biopharma to Host Extraordinary General Meeting for Shareholders to Discuss Merger LakeShore Biopharma announces an extraordinary meeting on February 12, 2026, to discuss a significant merger agreement with Oceanpine Skyline Inc.

LakeShore Biopharma to Host Extraordinary General Meeting for Shareholders to Discuss Merger #China #Beijing #LakeShore_Biopharma #Extraordinary_Meeting #Oceanpine_Skyline

LakeShore Biopharma Announces Major Shift to Private Ownership Through Merger Agreement LakeShore Biopharma is set to go private following a merger agreement with Oceanpine Skyline. Shareholders to receive cash per share.

LakeShore Biopharma Announces Major Shift to Private Ownership Through Merger Agreement #China #Beijing #Merger_Agreement #LakeShore_Biopharma #Oceanpine_Skyline

LakeShore Biopharma Faces Nasdaq Delisting Following Price Rule Violation LakeShore Biopharma, specialized in biopharmaceuticals, reveals its receipt of a delisting announcement from Nasdaq due to bid price compliance issues.

LakeShore Biopharma Faces Nasdaq Delisting Following Price Rule Violation #China #NASDAQ #Beijing #LakeShore_Biopharma #Delisting

LakeShore Biopharma Receives Revised Proposal for Acquisition and Forms Special Committee LakeShore Biopharma has received a revised proposal for acquisition from Oceanpine Capital and others. A special committee has been established to evaluate this proposal.

LakeShore Biopharma Receives Revised Proposal for Acquisition and Forms Special Committee #China #Beijing #LakeShore_Biopharma #acquisition_proposal #Oceapine_Capital

LakeShore Biopharma Receives Acquisition Proposal from Oceanpine Capital LakeShore Biopharma has received a preliminary non-binding proposal to be acquired for $0.86 per share, marking a 10.3% premium over recent prices.

LakeShore Biopharma Receives Acquisition Proposal from Oceanpine Capital #China #Beijing #LakeShore_Biopharma #Oceanpine_Capital #firm_acquisition

LakeShore Biopharma Reports Impressive Financial Growth for FY2025 LakeShore Biopharma announces its FY2025 financial results, showcasing robust revenue growth and improved profitability amidst market challenges. Significant strides in operational efficiency were evident.

LakeShore Biopharma Reports Impressive Financial Growth for FY2025 #China #Beijing #LakeShore_Biopharma #Fiscal_Year_2025 #rabies_vaccine

LakeShore Biopharma Secures $15 Million in Private Placement Financing with Institutional Investor LakeShore Biopharma has successfully closed a $15 million financing round with an institutional investor, bolstering its vaccine and therapeutic development endeavors.

LakeShore Biopharma Secures $15 Million in Private Placement Financing with Institutional Investor #USA #Beijing #biopharmaceuticals #Private_Placement #LakeShore_Biopharma

LakeShore Biopharma Unveils Innovative Packaging for YSJA Rabies Vaccine LakeShore Biopharma has launched a groundbreaking packaging solution for its YSJA rabies vaccine, enhancing vaccination safety. Discover its benefits here.

LakeShore Biopharma Unveils Innovative Packaging for YSJA Rabies Vaccine #China #Changsha #LakeShore_Biopharma #YSJA_vaccine #rabies_vaccine

LakeShore Biopharma Achieves Landmark Financial Milestones in H1 FY2025 LakeShore Biopharma reports impressive growth, achieving a significant financial turnaround with net income in H1 FY2025 amidst challenging conditions.

LakeShore Biopharma Achieves Landmark Financial Milestones in H1 FY2025 #China #Beijing #LakeShore_Biopharma #YSJA_Rabies_Vaccine #Fiscal_Year_2025